Abstract: The present invention relates to a class of substituted heterocyclic derivative and preparation method thereof.

Abstract: The present invention relates to a compound of formula I, a stereoisomer, a prodrug, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a process for preparing the same, a pharmaceutical composition comprising the same, and use of the compound in the preparation of medicine preventing and treating tumors, wherein the substituents are as defined in the specification.

Abstract: Disclosed are nanoparticles comprising octapod iron oxide having eight trigonal bipyramidal arms and a method of preparing the same. The nanoparticles are prepared by heating a mixture of a ferric carboxylate, a carboxylic acid, a chloride salt, water, and a non-polar solvent, to a temperature above about 300° C. Also disclosed is a method of magnetic resonance imaging a tissue in a mammal, comprising use of the aforesaid nanoparticles.

Abstract: The present invention relates to a method for quantitative detection of anti-HBc and its use in monitoring disease progression of chronic hepatitis B patients and predicting therapeutic effects. By quantitative detection of antibodies against hepatitis B core protein (Anti-HBc), it is able to monitor disease progression of chronic hepatitis B patients, effectively predict therapeutic effects in chronic hepatitis B patients who accept a therapy against hepatitis B virus (especially, a therapy based on interferon and a therapy based on nucleoside/nucleotide analog anti-HBV drug), and thus guide the patients to reasonably choose drugs.

Abstract: The invention relates to a method for preparing double-layered virus-like particles of rotavirus in vitro. The method comprises the following steps: purifying rotavirus VP6 proteins from a lysis supernatant, and in vitro assembling double-layered virus-like particles consisting of VP2 proteins and VP6 proteins, wherein the proteins and the virus-like particles can be used for preventing or reducing the clinical symptoms caused by rotavirus infection.

Abstract: The present invention provides application of camptothecin and derivatives thereof as antifouling agent, relating to camptothecin. Application of camptothecin and derivatives thereof as antifouling agent for facilities in water is provided, wherein the antifouling agent contains camptothecin and/or at least one of its derivatives. The application of camptothecin and derivatives thereof as antifouling agent for facilities in water can be used to prevent attachment of marine or freshwater micro-fouling organisms and/or large fouling organisms to the surfaces of facilities in the sea, lake, river or pool. The antifouling agent may also be used in mixture with other antifouling substance. Antifouling method for artificial facilities in water is provided. An antifouling paint for facilities in water is provided. Camptothecin and its derivatives have significant inhibitory activity to the attachment of fouling organisms, i.e.

Abstract: The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.

Abstract: The invention relates to antibodies recognizing epitopes on HA1 domain of hemagglutinin (HA) protein of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to HA1 domain of different HA subtypes and specifically bind to HA1 domain of hemagglutinin (HA) protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses. Therefore, the invention also relates to vaccines or pharmaceutical compositions for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g. influenza), comprising the antibodies according to the invention.

Abstract: The present invention provides a type of cost-effective sulfur-based transition metal composite as the negative electrode active material for lithium ion batteries with high capacity. Moreover, a non-aqueous secondary battery using this negative electrode with long cycle life and high capacity is provided. The battery contains a positive electrode, negative electrode, separator, and non-aqueous electrolytes. The negative electrode contains at least one kind of sulfur-based transition metal composites provided in the present invention.

Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.

Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 18, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.

Abstract: The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer.

Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.

Abstract: The present invention relates to a method and a kit for detecting nucleic acid sequence variation using melting curve analysis, especially relates to a method and a kit for detecting nucleic acid sequence variation by melting curve analysis using self-quenched probe. Said method provides the characteristics of the self-quenched probe employed, as well as the corresponding nucleic acid amplification conditions, so that the probe can bind to the amplified target sequence, and variations of the target sequence can be detected by melting curve analysis. The present invention also encompasses a kit assembled according to the method described.

Abstract: The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of the known monoclonal antibodies to the H5 subtype avian influenza virus hemagglutinin (HA) protein. The monoclonal antibodies can be used for the detection, diagnosis, prevention, and treatment of avian influenza viruses, especially the H5 subtype of avian influenza viruses. The present invention also provides the related hybridoma cell lines, isolated nucleic acid molecules and short peptides, as well as medical composition and medical diagnostic equipment and kit containing the monoclonal antibody.

Abstract: Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.

Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.

Abstract: A supercapacitor having a main energy storage form that is based on the electrode reaction of electrochemical active materials in a thin liquid layer near the inner and outer surfaces of porous electrodes.

Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.